Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC)

Blood (2012) 120 (21): 3949.

https://doi.org/10.1182/blood.V120.21.3949.3949

Published: 2012

Journal Articles

Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

Blood (2011) 118 (21): 991.

https://doi.org/10.1182/blood.V118.21.991.991

Published: 2011

Journal Articles

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Blood (2011) 118 (21): 476.

https://doi.org/10.1182/blood.V118.21.476.476

Published: 2011

Journal Articles

Maintenance Therapy with Bortezomib Plus Thalidomide (VT) or Bortezomib Plus Prednisone (VP) In Elderly Myeloma Patients Included In the GEM2005MAS65 Spanish Randomized Trial

María-Victoria Mateos, MD, PhD, Albert Oriol, Ana-Isabel Teruel, Enrique Bengoechea, Montse Pérez, Javier López, Joaquín Díaz-Mediavilla, Jose Mariano Hernández, Felipe de Arriba, Yolanda Gonzalez, Joan Bladé, MD, Juan José Lahuerta, JesÃ°s F. San Miguel

Blood (2011) 118 (21): 477.

https://doi.org/10.1182/blood.V118.21.477.477

Published: 2011

Journal Articles

Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose Therapy/Stem Cell Support (HDT/SCS): Results of the Spanish Trial (PETHEMA/GEM2000).

María-Victoria Mateos, MD, PhD, Juán-José Lahuerta, MD, PhD, Anna Sureda, MD, PhD, Javier de la Rubia, MD, PhD, Ramón García-Sanz, MD, PhD, Rafael Martínez, MD, PhD, José García-Laraña, MD, PhD, Felipe de Arriba, MD, PhD, Jose-María Ribera, MD, PhD, Miguel-Teodoro Hernández, MD, PhD, Lourdes Escoda, MD, PhD, Dolores Carrera, MD, PhD, Joan Besalduch, MD, PhD, B. Hernández, MD, PhD, P. Fernández, MD, PhD, Joan Blade, MD, PhD, J.F. San Miguel, MD, PhD

Blood (2007) 110 (11): 937.

https://doi.org/10.1182/blood.V110.11.937.937

Published: 2007

Journal Articles

Long Remission Are Possible after Non Myeloablative Transplant in Patients with Follicular Non-Hodgkin’s Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.

María-Dolores Caballero, MD, PhD, Rodrigo Martino, MD, María-Victoria Mateos, MD, Phd, Javier Briones, MD, Javier de la Serna, MD, Jose-Francisco Tomás, MD, Reyes Arranz, MD, Jose-Luis Díez, MD, Vicente Rubio, MD, Josep-María Ribera, MD, José-María Moraleda, MD, PhD, Guillermo Sanz, MD, Alvaro Urbano, MD, PhD, José Sarrá, MD, Antonia Sampol, MD, Jordi Sierra, MD, PhD, J. F. San Miguel, MD, PhD

Blood (2006) 108 (11): 3024.

https://doi.org/10.1182/blood.V108.11.3024.3024

Published: 2006

NARROW

Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC)

Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Maintenance Therapy with Bortezomib Plus Thalidomide (VT) or Bortezomib Plus Prednisone (VP) In Elderly Myeloma Patients Included In the GEM2005MAS65 Spanish Randomized Trial

Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose Therapy/Stem Cell Support (HDT/SCS): Results of the Spanish Trial (PETHEMA/GEM2000).

Long Remission Are Possible after Non Myeloablative Transplant in Patients with Follicular Non-Hodgkin’s Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.

Email alerts

ASH Publications

American Society of Hematology

Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC)

Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Maintenance Therapy with Bortezomib Plus Thalidomide (VT) or Bortezomib Plus Prednisone (VP) In Elderly Myeloma Patients Included In the GEM2005MAS65 Spanish Randomized Trial

Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose Therapy/Stem Cell Support (HDT/SCS): Results of the Spanish Trial (PETHEMA/GEM2000).

Long Remission Are Possible after Non Myeloablative Transplant in Patients with Follicular Non-Hodgkin’s Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only